Home / Positions + Comments / CPC Points to Consider on Co-Development / Companion Diagnostics

CPC Points to Consider on Co-Development / Companion Diagnostics

The CPC submitted this document to FDA in order to present its position on various issues FDA should consider when drafting Co-Development and Other Companion Diagnostic guidance including:

Companion diagnostics versus combination products.
De novo reclassification of companion diagnostics.
Evidence required for approval.
Labeling issues.